News

New CFO Arnd Christ to take up position at MediGene in April

Martinsried/Munich, April 19, 2010. The biotech company MediGene AG (Frankfurt, Prime Standard, TecDAX) today announces that the Company's new Chief Financial Officer Arnd Christ, whose appointment was announced in March, will succeed Dr. Thomas Klaue on April 19, 2010, and Dr. Klaue has therefore resigned with immediate effect. The appointment of Mr Christ was scheduled for May 11, 2010, and the change has become possible earlier because he has been able to terminate his previous employment as Chief Financial Officer at NovImmune AG in mid-April.

Prof. Dr. Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene AG, commented: "We are delighted to welcome Arnd Christ to MediGene as a respected financial professional with many years of experience in the biotechnology industry. His appointment successfully concludes the re-alignment of MediGene's Executive Board with the company's strategic refocusing which began in 2009. We remain confident in our ongoing drug development programs which are progressing according to schedule, and we would like to invite our shareholders to get a first-hand update of the company's progress at the upcoming annual shareholders meeting."

 

This press release contains forward-looking statements representing the opinion of MediGene as of the date of this release. The actual results achieved by MediGene may differ significantly from the forward-looking statements made herein. MediGene is not bound to update any of these forward-looking statements. MediGene is a registered trademark of MediGene. This trademark may be owned or licensed in select locations only.

- ends -

 

MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company to have drugs on the market which are distributed by partner companies. It has several drug candidates in clinical development and possesses innovative platform technologies. MediGene focuses on clinical research and development of novel drugs with focus on oncology.

 

Contact MediGene AG

Email: investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920

Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324

Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946